SPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001
ADVERTISEMENT
ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
SPIMA Therapeutics SA lauches with €1m investment by SATT AxLR, which has licenced the company’s lead programme, SP-001